Introduction
The human neurotropic JC virus (JCV) is the etiologic agent of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system (CNS) (Berger et al., 1998) . JCV is a member of the polyomaviruses whose other members include BK virus and the well-known simian virus 40 (SV40). JCV coexists within the human population, as greater than 80% of adults worldwide exhibit JCVspecific antibodies (Major et al., 1992) . Subclinical infection with the virus occurs in early childhood and the virus remains in a latent stage throughout life, although on rare occasions the virus becomes reactivated and causes PML when the immune system is impaired.
Prior to the AIDS epidemic, PML was considered an extremely rare disorder associated with immunocompromising diseases such as lymphomas, or was seen in renal transplant and chemotherapy patients as a complication of immunosuppressive therapies. However, recent reports indicate that 70% of all HIV-1-infected patients will exhibit neurological disorders and between 5 and 8% of all HIV-1-infected patients will develop PML (Berger and Concha, 1995) . PML is characterized by demyelination due to the cytolytic destruction of oligodendrocytes, the subset of glial cells in brain that are responsible for myelin production. Other hallmarks of PML include giant bizarre astrocytes, hyperchromatic oligodendrocyte nuclei, and multiple foci of demyelination (Major et al., 1992) .
The viral genome is comprised of a closed, circular, double-stranded DNA that can be divided into early and late coding sequences, and the viral regulatory region. The regulatory region of JCV encompasses the viral origin of DNA replication and a bidirectional promoter composed of two 98 base pair repeats. The viral early sequence that is transcribed before DNA replication is responsible for the production of Tantigen, whereas the viral late genes that are transcribed after DNA replication, produce capsid proteins VP1, VP2, and VP3 and the accessory Agnoprotein (Frisque and White, 1992) . The lytic cycle of JCV explains some of the pathological features of PML, hallmarks of which are the destruction of myelin sheaths and oligodendrocytes, the myelin-producing cells; and the appearance of astrocytes that exhibit transformed cell morphology. Evidently, lytic infection with JCV results in cytolytic destruction of oligodendrocytes, while its abortive replication in astrocytes causes morphological changes leaving astrocytes that resemble transformed cells. In cell culture systems, JCV exhibits a narrow tissue specificity in that the virus can replicate most efficiently in primary human fetal glial cells. Studies have also reported weak replication of the virus in B cells (Monaco et al., 1996) . Owing to the species specificity of the DNA polymerase, JCV can only replicate in primates, and humans are thought to represent the natural viral host (Frisque and White, 1992) .
In addition to its primary role in the development of PML, JCV has been shown to be associated with several human tumors (Del Valle et al., 2001a) . While the etiologic role for JCV in the development of cancer in humans remains to be established, there have been several experimental animal models that verify the oncogenic potential of JCV in vivo. Furthermore, the ability of the JCV early protein to transform human fetal cells has led to the development of several cell lines that possess tumorigenic activity in vivo. In this review, we have summarized the most recent observations on JCV-transformed tumor cells in which the viral protein, T-antigen deregulates several cellular pathways that control proliferation. These observations can provide an alternative working platform for studying oncogenic pathways utilized by various viruses to induce cancer in humans.
JCV and cancer: in vitro and in vivo observations
Similar to the well-studied SV40, JCV possesses the ability to infect and transform primary cultures, including primary human fetal glial cells and human vascular endothelial cells, albeit to a lesser degree than SV40 (Fareed et al., 1978; Walker and Padgett, 1978) . Almost all JCV-infected transformed cells express the viral early protein and they exhibit altered morphology, enhanced growth rate in low serum medium, the ability to form foci in culture, and in some but not all cases, induce tumors in Nude mice (Gallia et al., 1998a; Del Valle et al., 2001a) . Also, transformation of primary hamster brain cells by various strains of JCV, including Mad-1 and Mad-4, have generated rapidly growing cells with several characteristics of a transformed phenotype, including growth in low serum, enhanced production of plasminogen activator, and anchorage-independent growth (Frisque et al., 1980; Kang and Folk, 1992) . In addition to the cells of neural origin that seem to be readily transformed by the virus, a low incidence of JCV-mediated transformation in baby hamster kidney cells and in rat fibroblasts has been reported (Bollag et al., 1989; Haggerty et al., 1989) . In laboratory animals JCV infection often results in the development of tumors. Newborn Syrian hamsters develop a broad range of tumors, including medulloblastomas, primitive neuroectodermal tumors, astrocytomas, glioblastoma multiforme, and peripheral neuroblastomas after brain inoculation with JCV (Walker et al., 1973; Varakis, 1978; Zu Rhein and Varakis, 1979) . While no evidence for productive infection of the tumor cells by JCV has been observed, expression of the viral early, but not late, promoter in the tumor cells leads to the accumulation of large amounts of T-antigen (Raj et al., 1995) . Similarly, injection of JCV into the brains of newborn rats induces undifferentiated neuroectodermal tumors in the cerebrum of 75% of the animals (Ohsumi et al., 1986) . In owl and squirrel monkeys, intracerebral, subcutaneous, or intravenous inoculation of JCV causes the development of astrocytomas, glioblastomas, and neuroblastomas by 16-24 months of age (London et al., 1983) . In accord with the observations in the JCV hamster model, expression of the JCV early genome was observed in the absence of the viral late proteins and viral DNA replication ruling out productive infection of the tumor cells by JCV. Expression of the JCV early protein from the Mad-4 strain of JCV in transgenic animals containing only the early DNA sequences of JCV results in the development of two distinct phenotypes. One line exhibited dysmyelination of the central nervous system due to reduced production of myelin proteins, while the other set developed adrenal neuroblastoma (Small et al., 1986a, b; Franks et al., 1996) . Expression of the JCV early protein from the archetype strain of JCV in FVB/ N mice leads to the development of primitive neuroectodermal tumors resembling medulloblastoma (Krynska et al., 1999b) . Of note, no evidence for abnormal myelination of the brain was observed in transgenic mice harboring tumors. In a different series of studies, transgenic animals were created using the C57BL/6 mouse strain expressing the JCV Mad-4 early genome. After 6-8 months, the mice exhibited pituitary adenomas . Curiously, some of the animals that had not developed pituitary adenomas instead developed malignant peripheral nerve sheath tumors (MPNST) (Shollar and Gordon, unpublished observations). Histological examination of the various JCV-induced tumors in transgenic mice revealed that while all cells contain the transgene, as expected, only a subset of cells express T-antigen. Interestingly, results from studies on cell cultures derived from PNETs showed that after several passages, T-antigen-positive cells lose their expression of T-antigen, yet retain their transforming phenotype. While the mechanism involved in the extinction of T-antigen remains unknown, its has been suggested that a 'hit-and-run' mechanism may be involved in JCV-induced cancer cells. Results from in vitro studies have indicated that T-antigen-positive and T-antigen-negative medulloblastoma cells derived from transgenic mice exhibit similar growth patterns in monolayer cultures (Wang et al., 2001) . Under anchorage-independent growth conditions, however, the T-antigen-positive cells manage to survive in the absence of serum and proliferate upon treatment of cells with insulin-like growth factor 1 (IGF-1). Under similar conditions, T-antigen-negative cells demonstrate an attenuated response when stimulated with IGF-1 (Wang et al., 2001) . Similarly, T-antigen-positive cells form tumors when injected subcutaneously in Nude mice, while the T-antigen-negative cells show limited, if any, growth (Krynska et al., 2000) .
Molecular basis of JCV T-antigen-mediated transformation
While the precise mechanism responsible for cellular transformation by JCV is not fully understood, it is believed that the early proteins of the virus, particularly T-antigen, by associating with several cellular proteins, plays a critical role in this event (Sullivan et al., 2000) . Like SV40 T-antigen, JCV T-antigen has a modular structure with multifunctional activities including ATPase, helicase, DNA binding, and a-polymerase; all of which are essential for the process of DNA replication (Pipas, 1992; Sullivan et al., 2000) . Furthermore, results from protein-protein interaction studies revealed that JCV T-antigen has the capacity to interact with several critical tumor suppressor proteins including p53 and members of the pRb family (Bollag et al., 1989; Haggerty et al., 1989; Del Valle et al., 2001a) . It is believed that the association of T-antigen with p53 and the pRb family can lead to the inactivation of these tumor suppressors in cells expressing T-antigen and thus, promote uncontrolled proliferation. According to one model, the association of JCV T-antigen with p53 abrogates the ability of p53 to augment transcription of p21/WAF-1, an inhibitor of cyclin kinases, including cyclins A and E, and their associated kinases. Under normal conditions, a decrease in kinase activity of G1/S cyclins:cdks maintains pRb in a hypophosphorylated and active state that in turn sequesters the S phasespecific transcription factor, E2F. Not mutually exclusive, T-antigen's association with pRb can liberate E2F from the pRb:E2F complex and permit E2F to exert its affect on cell proliferation by promoting unscheduled transcription of S phase genes (Figure 1) . Support for pRb regulation of T-antigen-induced tumors comes from studies illustrating that overexpression of pRb2/ p130 can overcome JCV-T-antigen-mediated tumorigenecity in experimental animals (Howard et al., 1998) . JCV T-antigen has also been associated with other cellular proteins such as YB-1 and Pura (Gallia et al., 1998b; Safak et al., 1999) . The association of T-antigen with Pura is relevant to the transforming ability of T-antigen, as earlier results have demonstrated that Pura overexpression suppresses the growth of several tumor cells (Darbinian et al., 2001) . Thus, one may envision a role for T-antigen in the inactivation of Pura by association in cells in which Pura contributes to the control of cell proliferation. The cellular chaperone hsp70 and the insulin receptor substrate 1 (IRS-1), a key component of the type 1 insulin-like growth factor receptor (IGF-1R), have also been shown to associate with T-antigen (Baserga, 1999; Sullivan et al., 2000; Lassak et al., 2002) .
The association of T-antigen and IRS-1 is of particular interest as recent studies have suggested that the IGF-1 signaling pathway contributes to proliferation and survival of medulloblastoma cell lines (Patti et al., 2000; Wang et al., 2001; Del Valle et al., 2002a, b) . An abundance of IGF-1R, overexpression of IRS-1, and phosphorylation of IGF-1R and IRS-1 have all been detected in JCV T-antigen murine cell lines, suggesting that IGF-1R and T-antigen may cooperate in cellular transformation (Wang et al., 2001) . The use of an antisense strategy against IGF-1R mRNA and dominant-negative mutants for IGF-1R in in vivo and in vitro assays established the importance of IGF-1R in growth of JCV T-antigen tumor cells (Wang et al., 2001; Reiss 2002) . A Of interest, IRS-1 has been found in the nucleus of T-antigen-positive cell lines and human tumor samples, suggesting that T-antigen expression may lead to nuclear localization of IRS-1 (Del Valle et al., 2002a; Lassak et al., 2002 , Tu et al., 2002 . Mapping studies have determined that the N-terminal portion of IRS-1 interacts with JCV T-antigen and that this binding is independent from IRS-1 tyrosine phosphorylation and can be strongly inhibited by IRS-1 serine phosphorylation. Importantly, competition for IRS-1-T-antigen binding by a dominant-negative mutant of IRS-1 inhibited anchorage-independent proliferation of JCV T-antigen-transformed medulloblastoma cells (Lassak et al., 2002) . All of these observations have led us to propose a model in which the interaction of T-antigen and IRS-1 may lead to the uncoupling of IRS-1 from the IGF-1R and the translocation of IRS-1 to the nucleus (Figure 2 ). Further studies are needed to determine the nuclear function of IRS-1 in the presence and absence of JCV T-antigen.
In light of recent studies demonstrating the involvement of Wnt signaling in various cancers, including medulloblastomas (Morin, 1999; Eberhart et al., 2000) and the association of JCV with these tumors, it was hypothesized that JCV exerts its oncogenic activity, at least in part, through deregulation of the Wnt signaling pathway. In normal cells, b-catenin, a key modulator of the Wnt pathway, is modified on its N-terminal serine and threonine by phosphorylation and then ubiquitinated and rapidly degraded by the proteosome pathway (for review see Polakis 2000; Gao et al., 2002) . Degradation of b-catenin occurs by a multiprotein cytoplasmic complex containing GSK3b, Axin 1, and APC. When cells are stimulated by Wnt proteins, the function of the GSK3b/Axin1/APC complex is inhibited by a lesser known pathway leading to the accumulation of unphosphorylated and stable b-catenin in the cytoplasm. Cytoplasmic b-catenin translocates into the nucleus where it forms a heterocomplex with DNA binding transcription factors such as TCF/LEF, which have the potential to stimulate transcription of genes related to cell cycle regulation such as c-myc and cyclin D1 (He et al., 1998; Shtutman et al., 1999) . In several cancer cells, including PNETs, it was shown that mutations at the site of phosphorylation of b-catenin results in stabilization of b-catenin, its nuclear import, and enhanced expression of cell cycle regulators (Figure 3) . Examination of the Wnt signaling pathway in JCV Tantigen-positive cells compared to T-antigen-negative cells revealed enhanced levels of b-catenin, LEF-1, and their downstream target, c-myc, suggesting a role for Tantigen in deregulating the Wnt pathway (Gan et al., 2001) . Further studies have revealed the ability of Tantigen to associate physically with b-catenin and stabilize wild-type b-catenin. This event was concurrent with increased levels of b-catenin in the nucleus and enhancement of c-myc gene expression (Figure 3) .
Through alternative splicing, the early region of JCV can also encode several smaller isoforms of large T-antigen including small t-antigen and T (Bollag et al., 2000; Prins and Frisque, 2001) . Initial studies with the T 0 proteins have suggested that these proteins may contribute to replication of viral DNA and suspected to possess some oncogenic potential (Prins and Frisque, 2001) . Little is known about the function of JCV small t-antigen, and its potential role in cellular transformation. However, based on sequence homology between specific regions of SV40 and JCV small t-antigens, one may ascribe similar functions as those established for SV40 small t-antigen for the JCV protein. For example, the cysteines and the central proline of SV40 small t-antigen appear to be important for its interaction with and the inhibition of cellular phosphatase PP2A. As a consequence of PP2A inhibition by small t-antigen, several cellular kinases are hyperphosphorylated and their activity is elevated. This was first described for MAPK and its kinase, ERK, then extended to JNK and a key ion transporter, the Na/H antiporter (Sontag et al., 1993) . Activation of the MAPK family kinases by small t-antigen also leads to increased transcription from AP-1-driven promoters, consistent with activation of the Elk-1 family of transcription factors (Wheat et al., 1994) . Also, JCV small t-antigen may influence protein phosphorylation cascades involved in CREB-related transcriptional activities (Wheat et al., 1994) . In general, the effects of small t-antigen on intracellular kinases promote cell growth presumably by accelerating cell entry into the S phase by a complex mechanism that involves proteosome degradation of p27 (Sheaff et al., 1997) . Of note, efficient degradation of p27 is required for the accumulation of cyclin A and S phase progression (ZerfassThome et al., 1997). Thus, by favoring the elimination of p27, small t-antigen may allow cyclin A/cdk2 to orchestrate cell cycle progression.
In addition to multiple viral early proteins, the JCV late region encodes a small protein, named Agnoprotein, whose open reading frame resides in the leader of the late transcripts. In SV40, Agnoprotein plays a role in the lytic cycle of the virus by facilitating nuclear import of Figure 3 The Wnt signaling pathway. The Wnt signaling pathway and its well-studied cytoplasmic protein, b-catenin, is regulated by a series of proteins with kinase activity such as GSK3b, Axin, and APC. A mutation in b-catenin immunizes this protein against phosphorylation in which the stable proteins associate with LEF-1 and translocate to the nucleus where they stimulate c-myc, cyclin D1, and several other cell proliferation genes. JCV T-antigen, by associating with wild-type b-catenin, increases the stability of bcatenin and accelerates its nuclear import
Viruses and cancer K Reiss and K Khalili the capsid protein (Carswell and Alwine, 1986; Resnick and Shenk, 1986; Khalili et al., 1988) . Similarly, Agnoprotein plays a critical role in productive replication of JCV, as mutations in the Agnoprotein hamper replication of JCV in primary astrocytes (Safak et al., 2001, unpublished observations) . With respect to its effect on host cells, results from in vitro studies have demonstrated that the expression of Agnoprotein in cells leads to upregulation of cyclin A and p21/WAF-1. Interestingly, results from protein binding studies have revealed the ability of Agnoprotein to interact, although weakly, with p53, and that the region between residues 1-36 of Agnoprotein that contain a helix-loop-helix motif is essential for this interaction. Thus, it is evident that in addition to well-studied large T-antigen, other JCV proteins including small t-antigen, Agnoprotein, and perhaps T 0 may play a role in the oncogenic potential of this human polyomavirus.
Association of JCV with human cancer
As mentioned earlier, prior to the discovery of JCV, several reports indicated an association between PML and brain tumors. The first observations were made by Richardson in which the post-mortem examination of a 58-year-old man with chronic lymphocytic leukemia and PML revealed the presence of an oligodendroglioma (Richardson, 1961) . In other studies of PML cases associated JCV with multiple astrocytomas (Sima et al., 1983) and numerous foci of anaplastic astrocytes (Castaigne et al., 1974) were reported. In these cases, viral particles were observed in both oligodendrocytes and astrocytes, but not in the neoplastic astrocytes. Recently, Shintaku et al. (2000) reported a case of dysplastic ganglion-like cells in association with PML. Detailed immunohistochemical studies revealed that the neurons were infected with JCV and expressed JCV T-antigen in the absence of capsid protein, VP1.
In addition to cases of simultaneous PML and cerebral neoplasm, JCV has been found in human brain tumors in the absence of any PML lesions. In our recent work (Del Valle et al., 2001b) , 85 clinical specimens from the United Kingdom, Greece, and the United States have been examined for their possible association with JCV. These multiple samples represented various human brain tumors, including oligodendroglioma, astrocytoma, pilocytic astrocytoma, oligoastrocytoma, anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma multiforme, gliomatosis cerebri, gliosarcoma, ependymoma, and subependymoma. Gene amplification using primers that recognize the JCV DNA sequences followed by Southern blot hybridization have demonstrated the presence of the viral early sequences in 49 (69%) of 71 samples. More importantly, results of immunohistochemical analysis have demonstrated the expression of JCV T-antigen in the nuclei of tumor cells in 28 (32.9%) of 85 tested samples. In a separate series of studies, the presence of JCV in medulloblastomas has been established. Parallel reports demonstrate immunohistochemical detection of JCV T-antigen in 17.3 and 45% of samples obtained from two separate groups of medulloblastoma patients (Krynska et al., 1999a; Del Valle et al., 2002c) . In addition to T-antigen, analysis of medulloblastoma samples has revealed the presence of Agno DNA sequences in 11 (69%) out of 16 samples, and immunohistochemical analysis showed the presence of Agnoprotein in cytoplasm of 11 (55%) out of 20 samples. Importantly, the JCV early gene product, large T-antigen, was detected in nine (45%) out of 20 medulloblastoma cases examined.
In addition to tumors of the nervous system, more recent studies have detected JCV DNA sequences and expression of the viral proteins in colorectal carcinoma, rather than tumors arising from within the nervous system (Ricciardiello et al., 2001; Enam et al., 2002) . Greater than 50% of the tumor samples were found to express the viral proteins T-antigen and Agnoprotein, while a number of T-antigen-positive samples also contained b-catenin protein localized to the nucleus (Enam et al., 2002) . While VP-1 DNA sequences can be amplified from significant numbers of these tumors, VP1 expression by immunohistochemistry has not been observed in any tumor type, suggesting that the tumors cells are not productively infected with JCV, but rather transformed by the virus.
Interestingly, recent evidence has shown the presence of JCV in untreated urban sewage, suggesting transmission of the virus via the fecal-oral route (Bofil-Mas et al., 2001) . In addition, JCV DNA has also been found in the normal human gastrointestinal tract, which further supports the possibility that JCV, and other polyomaviruses, may colonize the gut (Ricciardiello et al., 2000) . These data, taken together with several reports of SV40 detection in human mesothelioma, osteosarcoma, and B-cell lymphoma, suggest that JCV may be observed within other tumor types throughout the body. The observations from such clinical samples along with the data from cell culture and experimental animals add further evidence of the involvement of JCV in the process of cellular transformation, and strongly suggest a possibility that this human neurotropic polyomavirus may play a role in the development of human brain tumors.
